Publications by authors named "Tom Ganten"

Claim this Profile
P
Prospective randomized controlled trial comparing a novel and dedicated device with conventional endoscopic techniques for the treatment of buried bumper syndrome (with video).
Andreas Wannhoff, Armin Küllmer, David Albers, Martin Fähndrich, Tom Ganten

Gastrointest Endosc· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Andreas A Schnitzbauer, Natalie Filmann, René Adam, Philippe Bachellier, Wolf O Bechstein, Tom M Ganten

Ann Surg· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Tom M Ganten, Rudolf E Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Jean-Frederic Blanc, Steven Miles, Tom Ganten, Jörg Trojan

Oncologist· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Inter-Laboratory Variability on Model of End-Stage Liver Disease (MELD) Score Calculation.
Mohammed Al-Saeedi, Taha Yassein, Daniel Schultze, Arash Nickkholgh, Helge Bruns, Tom M Ganten

Ann Transplant· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Michael Bitzer, Marius Horger, Edoardo G Giannini, Tom M Ganten, Marcus A Wörns

J Hepatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Maria-Katharina Ganten, Max Schuessler, Thomas Bruckner, Tom M Ganten, Ronald Koschny

Oncology· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Edward K Geissler, Andreas A Schnitzbauer, Carl Zülke, Philipp E Lamby, Andrea Proneth, Tom M Ganten

Transplantation· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Katrin Hoffmann, Tom Ganten, Daniel Gotthardtp, Boris Radeleff, Utz Settmacher

BMC Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.
Silvia von Karstedt, Annalisa Conti, Max Nobis, Antonella Montinaro, Torsten Hartwig, Tom M Ganten

Cancer Cell· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma.
Ronald Koschny, Wolfgang Krupp, Li-Xin Xu, Wolf C Mueller, Manfred Bauer, Tom M Ganten

Pathol Res Pract· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases.
Katrin Hoffmann, Ulf Hinz, Norbert Hillebrand, Tom Ganten, Daniel Gotthardt

Langenbecks Arch Surg· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
Ronald Koschny, Christina Boehm, Martin R Sprick, Tobias L Haas, Heidrun Holland, Tom M Ganten

J Neuropathol Exp Neurol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Elad Horwitz, Ilan Stein, Mariacarla Andreozzi, Julia Nemeth, Avivit Shoham, Tom Ganten

Cancer Discov· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver allocation: urgency of need or prospect of success? Ethical considerations.
Monika Bobbert, Tom M Ganten

Clin Transplant· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis.
Clemens Franz, Katrin Hoffmann, Ulf Hinz, Reinhard Singer, Ernst Hund, Tom Ganten

Clin Transplant· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Sylvia Brost, Anna Zimmermann, Ronald Koschny, Jaromir Sykora, Wolfgang Stremmel, Tom M Ganten

Pathol Res Pract· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of mycophenolate mofetil introduction in liver transplant patients: results from an observational, non-interventional, multicenter study (LOBSTER).
Hans J Schlitt, Sven Jonas, Tom M Ganten, Gerrit Grannas, Christian Moench

Clin Transplant· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.
Albader Albarmawi, David Czock, Annika Gauss, Robert Ehehalt, Justo Lorenzo Bermejo, Tom M Ganten

Br J Clin Pharmacol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Jan Pfeiffenberger, Ronald Koschny, Katrin Hoffmann, Arianeb Mehrabi, Anne Schmitz, Tom M Ganten

Langenbecks Arch Surg· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study.
Christian Georg Klein, Vito Cicinnati, Hartmut Schmidt, Tom Ganten, Marcus N Scherer

Ann Transplant· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma.
Ronald Koschny, Sylvia Brost, Ulf Hinz, Jaromir Sykora, Emanuela M Batke, Tom M Ganten

BMC Cancer· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis.
Alexandra Zahn, Franziska Müeller, Ulf Hinz, Peter Schemmer, Wolfgang Stremmel, Tom Ganten

Ann Transplant· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Katharina Esser-Nobis, Inés Romero-Brey, Tom M Ganten, Jérôme Gouttenoire, Christian Harak

Hepatology· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response.
Daniel Habermehl, Jürgen Debus, Tom Ganten, Maria-Katharina Ganten, Julia Bauer

Radiat Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis